HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


P&G’s Moeller Withstands NGO Charges Of Environmental Foot-Dragging, Stays Board Chair

Executive Summary

Procter & Gamble Co. shareholders elected 10 incumbent directors and one new director to the company’s board on 11 October, each receiving more than 90% of votes, the company says. NGOs pushed for changes, including CEO Jon Moeller’s replacement with an independent director, citing rising concerns about P&G’s forest sourcing practices.

You may also be interested in...

P&G’s 2022 Top Partners Include Oral B Maker In India, IFF Among First Sustainability Winners

Makers of oral care and grooming products, nutritional ingredient suppliers and packaging providers among Procter & Gamble’s 11 “Partner of the Year” award winners. International Flavors and Fragrances one of six winners in first year of “Supplier Sustainability Award.”

P&G ‘Clear-Eyed’ On Challenges Ahead; Growth Will Soften, But Strategic Priorities Go Unchanged

Environmental sustainability and DEI will remain key priorities for P&G as it enters a fiscal 2023 that augurs even greater volatility than 2022. The firm’s net sales for the 12 months ended 30 June increased 5%, or 7% organic, to $80.2bn, propelled by an 8% pricing increase in the fourth quarter.

Unilever Targets Sustainable Palm Oil Alternative With $120m Biotech Deal

Unilever PLC partners with biotechnology company Genomatica to fund and scale plant-based alternatives to palm oil for personal care and cleaning products.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts